CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
Autor: | Lisa A. King, Roeland Lameris, Tanja D. de Gruijl, Hans J. van der Vliet |
---|---|
Rok vydání: | 2018 |
Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine glycolipids Adoptive cell transfer Mini Review medicine.medical_treatment Immunology chemical and pharmacologic phenomena CD1d 03 medical and health sciences 0302 clinical medicine Immune system α galactosylceramide Cancer immunotherapy Antigen medicine Immunology and Allergy Cytotoxic T cell Theology Invariant natural killer T-cell iNKT cells Alpha-galactosylceramide cancer immunotherapy biology Chemistry Philosophy INKT Cells Correction Acquired immune system Chimeric antigen receptor carbohydrates (lipids) α-GalCer 030104 developmental biology CD1D biology.protein Cancer research lipids (amino acids peptides and proteins) lcsh:RC581-607 030215 immunology |
Zdroj: | Frontiers in Immunology, Vol 9 (2018) King, L A, Lameris, R, de Gruijl, T D & van der Vliet, H J 2018, ' CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy : α-Galactosylceramide and Beyond ', Frontiers in Immunology, vol. 9, 1519 . https://doi.org/10.3389/fimmu.2018.01519 Frontiers in Immunology |
ISSN: | 1664-3224 |
Popis: | CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid production of proinflammatory cytokines that trigger the cytotoxic machinery of other components of the innate and adaptive immune system. Here, we provide an overview of various therapeutic approaches that have been evaluated or that are currently being developed and/or explored. These include administration of α-GalCer or alternative (glyco) lipid antigens, glycolipid-loaded antigen-presenting cells and liposomes, strategies that enhance CD1d expression levels or are based on ligation of CD1d, adoptive transfer of iNKT cells or chimeric antigen receptor iNKT cells, and tumor targeting of iNKT cells. |
Databáze: | OpenAIRE |
Externí odkaz: |